Root causes of delays to access and unavailability of innovative medicines, have been identified by the European Federation of Pharmaceutical Industries and Associations (EFPIA):1 I. The time prior to marketing authorisation; II. The price and reimbursement process; III. The value assessment process; IV. Healthcare system constraints and resources; V. The sub-national approval process. Leaning into … Continued
Leaning into the root causes of delays to access (healthcare system constraints and the subnational approval process), we believe the solution lies in healthcare system thinking and subnational access methodologies. Our first principle of subnational access is that if patients are unable to reach the place in the care pathway or the clinic in the … Continued
Critical issues have emerged across healthcare systems, with the focus of health equity and health inequalities being of the highest priority. Health inequalities result in increased morbidity, decreased life expectancy and result in unwarranted variation across systems. THE IMPORTANCE OF HEALTH EQUITY AND TACKLING HEALTH INEQUALITIES Health equity is the most important factor in addressing … Continued
This week’s NHS ConfedExpo at the ACC in Liverpool was an opportunity for everyone in the healthcare industry to hear new ideas, share best practice and explore practical solutions to building for the future. Through its many sessions, and over 2 days, Accession took the opportunity to jump into the discussion and debate ………. here’s … Continued
With the American Society of Clinical Oncology (ASCO) 2022 coming to an end and being blown away by the development of innovative precision medicines, I couldn’t help but reflect on the challenges ahead for cancer services and the need to address them in order to effectively implement these new treatments. In their 2022/23 priorities and … Continued
On November 3rd 2017 the UK Government published its endorsement of the Accelerated Access Review (Making a reality of the Accelerated Access Review: Improving patient access to breakthrough technologies and treatments in a cost-effective model). At the core of the Accelerated Access Review is the proposal to get strategically important, cost-effective products into the NHS as … Continued
DISCOVER THE LATEST ARTICLES BY ACCESSION
Get in touch